In many cases, the target is a protein with activating mutations that is present only in tumor cells, facilitating the specificity of the therapy (for example, Braf-mutant melanomas, EGFR-mutant lung cancer), allowing profound inhibition of the target before the emergence of side effects. Here, EGFR is linked to neoplasm.